Targeting a protein involved in cancer treatment
A systems-level approach to therapeutically target STING in cancer
This study is looking at a new way to change a protein called STING that helps your immune system fight cancer, using a special technique to see how different changes can make cancer treatments work better for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10981389 on NIH RePORTER |
What this research studies
This research investigates a novel approach to target the STING protein, which plays a crucial role in the immune response against cancer. By utilizing a technology called SatSeq, the researchers aim to systematically alter the STING protein to understand its various functions in cancer therapy. This approach combines single-cell sequencing with saturation mutagenesis to explore how different modifications can enhance the immune system's ability to fight cancer. Patients may benefit from insights gained through this research that could lead to more effective cancer treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with cancer who may benefit from innovative immunotherapy approaches.
Not a fit: Patients with non-cancerous conditions or those who do not respond to immune-based therapies may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that enhance the immune response against cancer, potentially improving patient outcomes.
How similar studies have performed: Other research has shown promise in targeting immune pathways for cancer treatment, indicating that this approach could be a significant advancement in the field.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Laughney, Ashley Marie — Weill Medical Coll of Cornell Univ
- Study coordinator: Laughney, Ashley Marie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.